Merz Therapeutics North America

4 articles about Merz Therapeutics North America

• Merz Therapeutics to present robust data on XEOMIN® (incobotulinumtoxinA) at Toxins 2022 Conference in New Orleans, LA

  7/27/2022

  Merz Therapeutics announced today the presentation of data from 10 accepted abstracts on XEOMIN® (incobotulinumtoxinA) at TOXINS 2022

• Merz Therapeutics donates $100,000 to support construction of new rehabilitation center at University of North Carolina

  8/17/2021

  Merz Therapeutics announced today its U.S. organization has made a $100,000 donation to the University of North Carolina (UNC) Health Foundation

• Merz Therapeutics to present key data on XEOMIN® (incobotulinumtoxinA) at Toxins 2021 Virtual Conference

  1/15/2021

  18 accepted abstract presentations provide important updates and data on XEOMIN. Abstracts also published in Toxicon, a peer-reviewed interdisciplinary journal on toxins

• FDA Approves Pediatric Indication for XEOMIN® (incobotulinumtoxinA) for the Treatment of Chronic Sialorrhea

  12/21/2020

  Merz Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA)for XEOMIN® (incobotulinumtoxinA) for the treatment of patients aged 2 years and older with chronic sialorrhea, or droolin